Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas.
Publication
, Conference
Vredenburgh, JJ; Desjardins, A; Herndon, JE; Quinn, J; Rich, J; Sathornsumetee, S; Friedman, HS; Reardon, D; Gururangan, S; Friedman, A
Published in: JOURNAL OF CLINICAL ONCOLOGY
June 20, 2006
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
June 20, 2006
Volume
24
Issue
18
Start / End Page
59S / 59S
Location
Atlanta, GA
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
42nd Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Quinn, J., Rich, J., Sathornsumetee, S., … Friedman, A. (2006). Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 24, pp. 59S-59S). Atlanta, GA: AMER SOC CLINICAL ONCOLOGY.
Vredenburgh, J. J., A. Desjardins, J. E. Herndon, J. Quinn, J. Rich, S. Sathornsumetee, H. S. Friedman, D. Reardon, S. Gururangan, and A. Friedman. “Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas.” In JOURNAL OF CLINICAL ONCOLOGY, 24:59S-59S. AMER SOC CLINICAL ONCOLOGY, 2006.
Vredenburgh JJ, Desjardins A, Herndon JE, Quinn J, Rich J, Sathornsumetee S, et al. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2006. p. 59S-59S.
Vredenburgh, J. J., et al. “Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas.” JOURNAL OF CLINICAL ONCOLOGY, vol. 24, no. 18, AMER SOC CLINICAL ONCOLOGY, 2006, pp. 59S-59S.
Vredenburgh JJ, Desjardins A, Herndon JE, Quinn J, Rich J, Sathornsumetee S, Friedman HS, Reardon D, Gururangan S, Friedman A. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2006. p. 59S-59S.
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
June 20, 2006
Volume
24
Issue
18
Start / End Page
59S / 59S
Location
Atlanta, GA
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
42nd Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences